Clinical efficacy of levocarnitine supplementation in patients with hemodialysis

Clinical efficacy of levocarnitine supplementation in patients with hemodialysis - Levocarnitine on hemodialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015185

Enrollment

100

Registered

2014-09-17

Start date

2013-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis patients

Interventions

Levocarnitine injection 1000mg 3times weekly Control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Plasma free carnitine concentration less than 40 micro mol/L 2)duration of dialysis >12 months at enrollment 2)Patients who are treated with hemodialysis three times per week

Exclusion criteria

Exclusion criteria: (1) history of amputation of extremities or the presence of peripheral arterial disease; (2) a history of severe heart failure, angina, myocardial infarction, or stroke within the past 6 months; (3) the presence of infectious disease, thyroid disease, malignant tumors, or treatment with steroids or immunosuppressants; and (4) L-carnitine supplementation within the past 6 months.

Design outcomes

Primary

Measure	Time frame
cardiac function, renal anemia, atherosclerosis	—

Countries

Japan

Contacts

Public ContactMasanori Abe

Nihon University School of Medicine Department of Nephrology, Hypertension, and Endocrinology

abe.masanori@nihon-u.ac.jp+81-3-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026